Contingencies and commitments (Details) - USD ($) $ in Thousands |
Jun. 30, 2026 |
Dec. 31, 2025 |
Jun. 30, 2025 |
Dec. 31, 2024 |
Oct. 31, 2014 |
|---|---|---|---|---|---|
| Contingencies and Commitments [Line Items] | |||||
| Fair value of contingent consideration | $ 8,817 | $ 8,395 | $ 10,784 | $ 10,225 | |
| Recurring | |||||
| Contingencies and Commitments [Line Items] | |||||
| Fair value of contingent consideration | 8,817 | $ 8,395 | |||
| Enantigen's Selling Shareholders | Recurring | |||||
| Contingencies and Commitments [Line Items] | |||||
| Fair value of contingent consideration | $ 8,800 | $ 0 | |||
| Enantigen's Selling Shareholders | Arbutus Inc. | |||||
| Contingencies and Commitments [Line Items] | |||||
| Development and regulatory milestones payment per licensed compound series, maximum | 102,500 | ||||
| Development and regulatory milestones payment per royalty, maximum | $ 1,000 |